Radioembolization in the Treatment of Neuroendocrine Tumor Metastases to the Liver

Table 1

Study outcomes of TARE for NET liver metastases.

Lead Author, Year	𝑛	Prospective?	Treatment Phase	ORR	SD	Symptom Response	Survival
Arslan, 2011 [17]	10	No	?	80%	10%	NR	All alive at 4–28 mo
Cao, 2010 [15]	51	No	?	38%	27%	NR	36 mo
Saxena, 2010 [26]	48	No	?	55%	23%	NR	35 mo
Kalinowski, 2009 [19]	9	Yes	Refractory	66%	33%	Improved QoL	57% alive at 36 mo
Kennedy, 2009 [27]	148	No	Refractory/salvage	63.2%	22.7%	NR	70 mo
King, 2008 [22]	34	Yes	First-line*	50%	14.7%	50%	59% alive at 37 ± 2 mo
Murthy, 2008 [16]	8	No	Refractory/salvage	12.5%	50%	NR	14 mo
Rhee, 2008 [23]	20; 22**	Yes; Yes	Refractory; Refractory	50%; 53.8%	44%; 38.5%	NR; NR	28 mo; 22 mo
Meranze, 2007 [24]	10	Yes	First-line	40%	60%	Improved QoL	70% alive at 35 mo
McGrath, 2007 [25]	26	No	First-line/refractory	58.3%	33%	NR	69% alive at 17.3 mo
Kennedy, 2006 [21]	18	No	First-line/refractory	89%	NR	NR	89% alive at 27 mo

*combined with 5-FU.
**with Yttrium-90 glass microspheres, all others with Yttrium-90 resin microspheres. Median survival in last column unless otherwise indicated. ORR: objective response rate (complete + partial response). SD: stable disease. NR: not reported. QoL: quality of life.